Trump tariff pressure: AstraZeneca to move production to US, announces $50 billion manufacturing push
AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment. This move aligns with the company’s expectation that 50% of its revenue will come from the U.S. by 2030. The decision comes amid rising tariff pressures from the Trump administration, aiming to bolster domestic drug supply chains.🕒 1 min read
AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment. This move aligns with the company’s expectation that 50% of its revenue will come from the U.S. by 2030. The decision comes amid rising tariff pressures from the Trump administration, aiming to bolster domestic drug supply chains.
Continue Reading
-
Janhvi Kapoor’s Modern Princess Moment In Fairytale Lehenga
- Virat Kohli Sends Special Message To Smriti Mandhana-Led RCB After WPL 2026 Title Win
- India Inc credit profile gets boost from steady demand
-
How Sharad Pawar Became Maharashtra Opposition’s Rajya Sabha Candidate: Inside Story
-
“Have Decided To Remove ‘Terror Thorn’ From India”: PM Modi’s Vow In Gujarat
- Sharad Navratri 2025: Explore New Thalis And Menus At Top Restaurants Across India
- Meet Shivam Shukla, Another Mystery Spinner Roped In By KKR As Replacement Player In IPL 2025
- Piyush Goyal To Visit UK To Discuss Trade Pact Implementation
- Trump tariffs: Container freight rates likely to remain subdued amid uncertainty
- Lip balm on the field! KL Rahul vs Shubman Gill banter goes viral
